Bio-engineered Stent Market to Surpass US$ 5,841.8 Billion by 2026 - Coherent Market Insights

The global bio-engineered stent market, by Application Type (Coronary Artery Disease, Peripheral Arterial Disease, Carotid Artery Disease, Renal Artery Stenosis, Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Others), by Product Type (Drug-eluting Stents, Bioabsorbable Stents, and Drug-eluting Balloons), by Mode of Delivery (Balloon-expandable Stents and Self-expanding Stents), by Material Type (Metal-based and Polymer-based), by End User (Hospitals & Cardiac Centers and Ambulatory Surgical Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,764.2 million in 2017, and is projected to exhibit a CAGR of 8.7% over the forecast period (2018 – 2026). Launch of novel bio-engineered stent systems is expected to augment the market growth Key players in the market are focused on launching novel bio-engineered stent in order to reduce thrombus accumulation and address the critical unmet needs of patients in venous access. For instance, in May 2018, Abbott received the U.S. Food and Drug Administration (FDA) approval for XIENCE Sierra, a gold-standard XIENCE everolimus-eluting coronary stent system. Similarly, in May, 2018, Pursuit Vascular, Inc., received the U.S. FDA clearance for broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients. In May 2017, Medtronic, Plc. received the U.S. FDA approval for its Resolute Onyx, a 2.0mm size zotarolimus-eluting stent with unique continuous sinusoid technology.

Browse 25 Market Data Tables and 29 Figures spread through 176 Pages and in-depth TOC on 'Bio-engineered Stent Market'- Global Forecast to 2026 by Application Type by Application Type (Coronary Artery Disease, Peripheral Arterial Disease, Carotid Artery Disease, Renal Artery Stenosis, Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Others), by Product Type (Drug-eluting Stents, Bioabsorbable Stents, and Drug-eluting Balloons), by Mode of Delivery (Balloon-expandable Stents and Self-expanding Stents), by Material Type (Metal-based and Polymer-based), by End User (Hospitals & Cardiac Centers and Ambulatory Surgical Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)  

To know the latest trends and insights prevalent in the bio-engineered stent market, click the link below:

https://www.coherentmarketinsights.com/market-insight/bio-engineered-stent-market-2484

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in February 2016, Maquet Medical Systems, a Getinge Group Company, announced plans to enter into partnership with Biotronik, a Germany-based manufacturer of cardiovascular and endovascular medical devices, to distribute Biotronik’s peripheral vascular devices in the U.S.

Key Takeaways of the Bio-engineered Stent Market:

• The global bio-engineered stent market is expected to exhibit a CAGR of 8.7% over the forecast period, owing to increasing prevalence of cardiovascular diseases such as coronary heart disease and ischemic heart disease
• Among Application type, the coronary stents segment held a dominant position in the bio-engineered stent market in 2018, owing to increasing incidence of coronary artery disease and technological advancements in coronary stents
• Among product type, the bioabsorbable stents segment held a dominant position in the bio-engineered stent market in 2018. This is owing to increasing preference for bioabsorbable stents as they gradually get dissolved and enable the artery to return to its natural state.
• Among mode of delivery, the balloon-expandable stents segment held a dominant position in the bio-engineered stent market in 2018, as balloon-expandable stents offer greater compatibility, good flexibility, thereby offering high safety to patients
• Among Material Type Type type, the polymer-based segment held a dominant position in the bio-engineered stent market in 2018, due to its comparative advantages over metallic type
• Key players operating in the global bio-engineered stent market include, Medtronic, plc., Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, MicroPort Scientific Corporation, Stentys sao, Meril Life Sciences Pvt. Ltd, Vascular Concepts, W. L. Gore and Associates, C. R. Bard, Endologix, Inc., Lombard Medical Technologies, Translumina GmbH, and Jotec GmbH